In a 72-week trial, people taking Zepbound lost 50 pounds on average, compared with about 33 pounds for people taking Wegovy.

According to the Associated Press, trial participants received weekly injections of the highest tolerated doses of Zepbound, ...

A study of two blockbuster weight-loss drugs showed that users of Eli Lilly’s Zepbound lost just over 2 inches more off their waists compared with Novo Nordisk’s rival Wegovy. At 72 weeks, ...

The trial randomized 751 participants across the U.S. and Puerto Rico in a 1:1 ratio to receive maximum tolerated dose of Zepbound (10 mg or 15 mg) or Wegovy (1.7 mg or 2.4 mg). With tirzepatide ...

The obesity drug helped people trim about two inches more off their waists than Wegovy in the first head-to-head study of the ...

The first clinical trial comparing semaglutide and tirzepatide, two popular, injectable weight-loss drugs, has been published ...

Zepbound outperformed Nordisk's Wegovy in terms of weight loss, solidifying Lilly's leadership in the anti-obesity drug ...

Tirzepatide (Zepbound) came out on top against semaglutide ... Participants received a maximum tolerated shot of tirzepatide (10 mg or 15 mg) or the maximum tolerated shot of semaglutide (1.7 ...

A new study shows that people Zepbound lost about 50% more weight than those using Wegovy. It was the first head-to-head ...

In an emailed comment, Novo Nordisk said the Eli Lilly trial evaluated the maximum dose of Zepbound 10 mg or 15 mg to 1.7 mg or 2.4 mg in semaglutide. "The highest dose of tirzepatide is five ...

In today’s Health Alert, two popular weight loss drugs went head-to-head in a clinical trial – and one came out on top.